Hisashi Saji

Prof. Dr. Hisashi Saji

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2002 in Chest
Verified
Journal Article
Closed access
PDF file
HSHisashi Saji
Hisashi Saji
HNHaruhiko Nakamura
Haruhiko Nakamura
TTTakaaki Tsuchida
Takaaki Tsuchida
MTMasahiro Tsuboi
Masahiro Tsuboi
NKNorihiko Kawate
Norihiko Kawate
HKHarubumi Kato
Harubumi Kato

1 October 2010 in Interactive CardioVascular and Thoracic Surgery
Verified
Journal Article
Open access
PDF file
HSHisashi Saji
Hisashi Saji
KFKinya Furukawa
Kinya Furukawa
HTHidemitsu Tsutsui
Hidemitsu Tsutsui
MTMasahiro Tsuboi
Masahiro Tsuboi
SIShuji Ichinose
Shuji Ichinose
NINorihiko Ikeda
Norihiko Ikeda
Approximately 30% of lung cancer patients will develop central airway obstruction (CAO). Interventional therapeutic bronchoscopy including airway ste

1 November 2011 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
PDF file
HSHisashi Saji
Hisashi Saji
MTMasahiro Tsuboi
Masahiro Tsuboi
KYKoichi Yoshida
Koichi Yoshida
YKYasufumi Kato
Yasufumi Kato
MNMasaharu Nomura
Masaharu Nomura
NINorihiko Ikeda
Norihiko Ikeda

1 June 2013 in Chest
Verified
Journal Article
Closed access
HSHisashi Saji
Hisashi Saji
MTMasahiro Tsuboi
Masahiro Tsuboi
YSYoshihisa Shimada
Yoshihisa Shimada
YKYasufumi Kato
Yasufumi Kato
KYKoichi Yoshida
Koichi Yoshida
NINorihiko Ikeda
Norihiko Ikeda

1 January 2010 in Anti-Cancer Drugs
Verified
Journal Article
Closed access
HSHisashi Saji
Hisashi Saji
MTMasahiro Tsuboi
Masahiro Tsuboi
JMJun Matsubayashi
Jun Matsubayashi
KMKuniharu Miyajima
Kuniharu Miyajima
YSYoshihisa Shimada
Yoshihisa Shimada
NINorihiko Ikeda
Norihiko Ikeda
Patients with large cell neuroendocrine carcinoma (LCNEC) of the lung are considered to have poor prognosis. However, the benefit of adjuvant chemotherapy for these patients has not been established. In this study, we retrospectively evaluated the efficacy of perioperative chemotherapy for patients with completely resected LCNEC in a single-center setting. From 1999 through 2007, 45 patients with surgically resected LCNEC or mixed LCNEC containing at least one portion of the neuroendocrine differentiation or morphology in non-small cell lung carcinoma were enrolled as participants of this study. Survival rates were calculated by the Kaplan-Meier method. Differences between survival curves were computed with the log-rank test. For multivariate analysis, the Cox's proportional hazards regression model was used to evaluate variables that were significant predictors of survival. Of 1397 patients undergoing surgical resection for primary lung cancer from 1999 to 2007, 45 (3.2%) were classified as LCNEC. Thirty-six (80%) patients were men, and nine (20%) were women. Twenty-four (92%) of 26 patients were present or past smokers. Twenty-three (41%) of 45 patients received perioperative chemotherapy, including seven induction chemotherapies and 16 adjuvant chemotherapies. Survival of patients who underwent perioperative adjuvant chemotherapy was significantly higher than that of those who received surgery alone (P = 0.04). The 5-year survival rate of patients who underwent perioperative adjuvant chemotherapy was 87.5%, whereas that of patients who underwent surgery alone was 58.5%. Even in stage I cases, perioperative adjuvant chemotherapy still favors survival compared with surgery alone. In the Cox proportional hazard multivariate analysis, surgery with or without chemotherapy showed an independent prognostic influence on overall survival (P = 0.0457). Patients who received surgery alone were 9.5 times more likely to die than patients who underwent surgery plus chemotherapy. In conclusion, perioperative chemotherapy will be needed to improve survival in patients with LCNEC. As the population of LCNEC is small, it has been difficult to conduct randomized controlled trials to show the survival benefit of adjuvant chemotherapy. This should be, therefore, evaluated further in prospective multi-institutional phase II trials.

11 December 2017 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Closed access
PDF file
HSHisashi Saji
Hisashi Saji
TUTakahiko Ueno
Takahiko Ueno
HNHiroshige Nakamura
Hiroshige Nakamura
NONorihito Okumura
Norihito Okumura
MTMasanori Tsuchida
Masanori Tsuchida
MCMasayuki Chida
Masayuki Chida
Although some retrospective studies have reported clinicopathological scoring systems for predicting postoperative complications and survival outcomes for elderly lung cancer patients, optimized scoring systems remain controversial. The Japanese Association for Chest Surgery (JACS) conducted a nationwide multicentre prospective cohort and enrolled a total of 1019 octogenarians with medically operable lung cancer. Details of the clinical factors, comorbidities and comprehensive geriatric assessment were recorded for 895 patients to develop a comprehensive risk scoring (RS) system capable of predicting severe complications. Operative (30 days) and hospital mortality rates were 1.0% and 1.6%, respectively. Complications were observed in 308 (34%) patients, of whom 81 (8.4%) had Grade 3–4 severe complications. Pneumonia was the most common severe complication, observed in 27 (3.0%) patients. Five predictive factors, gender, comprehensive geriatric assessment75: memory and Simplified Comorbidity Score (SCS): diabetes mellitus, albumin and percentage vital capacity, were identified as independent predictive factors for severe postoperative complications (odds ratio = 2.73, 1.86, 1.54, 1.66 and 1.61, respectively) through univariate and multivariate analyses. A 5-fold cross-validation was performed as an internal validation to reconfirm these 5 predictive factors (average area under the curve 0.70). We developed a simplified RS system as follows: RS = 3 (gender: male) + 2 (comprehensive geriatric assessment 75: memory: yes) + 2 (albumin: <3.8 ng/ml) + 1 (percentage vital capacity: ≤90) + 1 (SCS: diabetes mellitus: yes). The current series shows that octogenarians can be successfully treated for lung cancer with surgical resection with an acceptable rate of severe complications and mortality. We propose a simplified RS system to predict severe complications in octogenarian patients with medically operative lung cancer. JACS1303 (UMIN000016756)